Galera settles Phase 3 ROMAN trial CRO lawsuit for $975,000

Galera Therapeutics, Inc.

Settlement with Alira Health Clinical and IQVIA Biotech resolves breach-of-contract and negligence claims.
CROs paid $975,000 in exchange for mutual releases and termination of contracts with no further obligations.
Lawsuit stemmed from a 2021 error in statistical programming for the Phase 3 ROMAN trial of avasopasem.
Galera expects to file a Praecipe to end the litigation by August 8, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.